TPS5605 Background: This phase 1 study (NCT02480374) evaluates the use of weekly intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in combination with dose-dense weekly taxane and carboplatinum (T/C) every three weeks in newly diagnosed epithelial ovarian, fallopian tube or primary peritoneal (EOC) cancer patients undergoing neoadjuvant therapy (NAC). Previous phase I study in platinum-sensitive EOC patients (n = 13) with escalating GEN-1 doses to 24 mg/m2 in combination T/C had an anti-tumor response of 17% complete response, 33% partial response and 42% stable disease (Anwer K. Gynecol Oncol. 2013 Oct;131(1):169-73). The primary objective of this study is to evaluate the tolerability and safety of GEN-1 with NAC in order to proceed with a phase 2 study. Secondary objectives are progression-free survival, pathological complete response, and response by CA-125. Translational research objectives include measuring levels of IL-12, IFN-γ, TNF-α, IL-10, TGF-β, and VEGF, determining the density of a wide range of immune activating and immune suppressing cells, and a comprehensive mRNA transcript panel for gene expression profile in the peritoneal cavity. Methods: Patient eligibility criteria: Females age > 18 years with newly diagnosed epithelial EOC not amenable to primary cytoreduction. Patients must not be on chronic steroids and have adequate renal, bone marrow, hepatic and neurologic functions. This protocol is a standard 3+3 design with a planned sample size up to 30 patients. Patients will receive GEN-1 at escalating dose levels from 36 mg/m2, 47 mg/m2, 61 mg/m2, 79 mg/m2, to 103 mg/m2 weekly for 8 treatments with concurrent T/C. After interval debulking patients do not receive further GEN-1 but continue on T/C. Patients are assessed for dose limiting toxicities and have tumor samples at time of diagnostic laparoscopy and interval debulking. After completion of therapy, patients are followed for every 3 months 2 years. As of January 31, 2016, 2 patients have completed dose level 1 and study enrollment continues. Clinical trial information: NCT02480374.